Call Us      +44 (0)20 70961222

event-logo-InnovSpotlight

In association with:

JOIN OUR INNOVATION SPOTLIGHT 2018 STRATEGY MEETING


16th May 2018, Marriot San Francisco Union Square, San Francisco

OUR UNIQUE FORMAT

In today’s fast-changing world, to stay competitive means to be innovative and open to embrace new approaches. Industry is facing time-pressing competition when fast movement through exploratory clinical phase is posing great challenges. Early go/no-go decisions have become critical. This is in contrast to dropping efficiency of clinical operations, constantly increasing complexity of study protocols and skyrocketing costs.

Industry thought leaders will gather for a one-day series of roundtable discussions to exchange their vision of paradigm shifts in early clinical that are already underway and yet to happen. The focus will be on practical aspects of implementation of innovative approaches to achieve Proof of Concept results in record time. We will share best practices and real-life case studies, exploring them from different perspectives – regulatory, sponsor, clinical site and patient.

Attendees will be able to address these issues and leave the day better informed on how to:

strategy-one

Develop an efficient strategy to Proof of Concept ( First-in-Man -> First-in-Patient): classical approach vs. “umbrella” protocols

overcome

Overcome challenges in execution of exploratory protocols: from feasibility stage to successful patient enrolment in Phase 1b/2a studies. Case studies from oncology, immunology and infectious diseases.

navigate

Navigate in the new EMA legislation on Phase 1 clinical trials following the incident in Frances

balance

Balance scientific/business interests & regulatory requirements

FACILITATORS
Claudia-Hesselmann

Claudia Hesselman

Co-Founder & Chief Executive Officer

ARENSIA

Andreas-Koester

Andreas Koester

Vice President, Clinical Innovation

Johnson & Johnson

Chris-Westland

Chris Westland

Associate Director, Clinical Operations

Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies

Yu Liang

Yu Liang

Director Clinical Biomarkers

Calithera Biosciences

Tatiana Eidus

Tatiana Eidus

Director Corporate Development

ARENSIA Exploratory Medicine Inc, Boston, USA

WHAT TO EXPECT
roundtable
Interactive Roundtable Discussions

Attendees can proactively share and ask questions to their peers about the success of their work in an informal setting.

one to one copy
Director level one-to-one meetings

We provide opportunities to engage with one another in our strategy meeting in a series of pre-arranged business meetings by interacting face to face.

agenda
Tailor-fit and Personalized Agenda

Being able to experience different sessions is what makes our event unique that’s why our attendees can personalize and select sessions they want to participate in.

netwkorking copy
Networking Opportunities

Several networking opportunities are in store for attendees to connect and build new relationships with their peers through luncheons, cocktails and informal introductions.

WHAT PEOPLE SAY

Pharma Supply Chain EU 2016 ,  Return on Investment attained at the meeting and why they are coming back

Pharma Supply Chain EU 2016 , Return on Investment attained at the meeting and why they are coming back

Pharma Supply Chain EU 2016 , What they think of the roundtable discussion format

Pharma Supply Chain EU 2016 , Level of delegation, attendee diversity and seniority

Pharma Supply Chain EU 2016 , Return on Investment attained at the meeting and why they are coming back

Pharma Supply Chain EU 2016 , What they think of the roundtable discussion format

Yaron Turpaz

Chief Information Officer

Its nice because they basically allowed people to engaged to discussions and questions. Academic and industry is very nice and informative

Ivan John Clement

Data Scientist - R&D

Its good because you really get the people to talk. They are willing to share their knowledge, the juniors are very eager to learn.

Raghuraman Gopal

Manager Quality Assurance

The format is the beginning of breakthrough and integration, the level of delegates is very good and excellent, they learn a lot.

Dadabhai Singh

Founder & President

The kind of interaction is very interactive

Steve Rozen

Director & Professor

Because of diversity we really districts the points and all. People are very diversity and thoughtful in a round table.

THE VENUE

MARRIOTT SAN FRANCISCO UNION SQUARE


Address

San Francisco Marriott Union Square, 480 Sutter Street, San Francisco, CA, 94108


Phone

+1 415 398 8900







Milan-Paleja

Milan Paleja

Country President & General Manager

, Novartis

Chris-Westland

Chris Westland

Associate Director, Clinical OperationsAlios BioPharma, Inc., part of the Janssen
Pharmaceutical Companies

Yu Liang

Yu Liang
Director Clinical Biomarkers

Calithera Biosciences

Claudia-Hesselmann

Claudia Hesselman

Co-Founder and Chief Executive Officer

ARENSIA

Tatiana-Eidus-150×150

Tatiana Eidus

Director Corporate Development

Arensia  Exploratory Medicine Inc. Boston USA

ARENSIA

Andreas-Koester

Andreas Koester

Vice President, Clinical Innovation

Johnson & Johnson

As Global Head of Janssen Clinical Innovation, Andreas is leading Janssen’s efforts to optimize the clinical trial process based on his 20+ years experience in pharmaceutical companies and CROs (Contract Research Organizations).  Andreas is passionate about improving the way pharma runs clinical trials for the benefit of our two key partners: patients and investigators.  Within J&J, he focuses on developing capabilities and processes that streamline the clinical trial process and bring medical innovations to patients faster.  While the majority of these efforts is targeted at late stage development, he also created an ED team in San Diego, modeled after Lilly’s CHORUS, to run early phase studies using a biotech like approach.

Linda-Burgoyne-Matilda-Hospital-270×260

Linda Burgoyne

Chief Executive Officer, Singapore Clinical Research Institute Matilda

International Hospital

Linda is a highly experienced healthcare professional with a passion for providing the best patient experience. Linda is an RM, RGN with a Masters in Communication Management (Australia) and holds an honorary professorship at HK University. She has held senior leadership positions in Europe, Middle East and currently Hong Kong. She is active in health care in the region and is instrumental in consistently maintaining high patient involvement and staff fulfilment, fortifying the Matilda International Hospitals competitive market position as HK premier hospital.

Dr.-Yee-Leong-Teoh-248×260

Dr. Yee Leong Teoh

Chief Executive Officer, Singapore

Clinical Research Institute

José is Global Head of Computer Aided Drug Discovery (CADD) at the Novartis Institutes for BioMedical Research (NIBR). José joined Novartis in 2010. Previously he had been with the Schering-Plough Research Institute and Merck Research Laboratories in Kenilworth, NJ, USA for 10 years where he had increasing responsibilities in the CADD group. His scientific fields of expertise within computational chemistry comprise molecular thinking, modeling, ab initio calculations, molecular recognition, QM-MM methods, solvation and structure-based drug design. José is passionate about drug discovery. He received his Ph.D. in Chemistry from the National University of Córdoba, Argentina. He joined Prof. Tony Hopfnger’s group in the College of Pharmacy at the University of Illinois

Alexander-Debets-2-270×260

Jeffrey Scott Yablon

Executive Vice President & Managing Director

InClinica

José is Global Head of Computer Aided Drug Discovery (CADD) at the Novartis Institutes for BioMedical Research (NIBR). José joined Novartis in 2010. Previously he had been with the Schering-Plough Research Institute and Merck Research Laboratories in Kenilworth, NJ, USA for 10 years where he had increasing responsibilities in the CADD group. His scientific fields of expertise within computational chemistry comprise molecular thinking, modeling, ab initio calculations, molecular recognition, QM-MM methods, solvation and structure-based drug design. José is passionate about drug discovery. He received his Ph.D. in Chemistry from the National University of Córdoba, Argentina. He joined Prof. Tony Hopfnger’s group in the College of Pharmacy at the University of Illinois

Mohd-Fauzi-Wahab-270×260

Mohd Fauzi Wahab

Vice President, Human Resources, Zuellig Pharma

 

Jacob-Jacob-270×260

Jacob Jacob

Group Chief Human Resource Officer

Columbia Asia Healthcare Sdn Bhd.

Jacob has over 21 years of experience varied across HR Consulting, International HR, Start Up HR and large scale Change Management HR. His core strengths lie in the areas of Change Management, Performance Management, Competency mapping & its applications, HR Strategy & Organisational Design. He has previously worked with organisations such as Apollo Hospitals Enterprise Ltd, Emirates Airline in Dubai, Feedback Ventures & Oberoi Realty. Currently, he works in Columbia Asia, his mandate is to create HR as an Innovative Centre of Excellence and build enterprise growth connecting people and performance.

He is also the recipient of several National and International Awards namely:
- Most Influential HR leader in India by World HR Congress 2017
- Recognized as one amongst the most powerful HR professionals in India by the World HR Congress 2013, 2010
- HR Leadership Award at the Asia Pacific Summit 2011
- HR professional of the Year for 2012
- Contribution to Organisation Award – Asia HRD Congress 2013, Jakarta

Jenny-Leo

Jenny Leo

Human Resource Director

Astrazeneca

Jenny has over 20 years of experience in human resources management in areas such as talent management, workforce planning, recruitment, and employee relations with the last 10 years focusing on compensation and benefits management and global mobility for the Asia Pacific region. She was leading the compensation and benefits function for Asia Pacific in Covidien and Kraft Foods for Asia Pacific, and she was the Human Resource Manager for Baxter Healthcare.

As the HR Director for Astrazeneca Asia since 1 April 2014, Jenny has been leading the Asia Area HR function and supporting the business in driving the people agenda. Prior to this, Jenny joined AstraZeneca in May 2011 as the Regional Compensation Director for Asia Pacific & Japan. In this role, she helped set up the Compensation COE team for Asia Pacific and led various initiatives including shaping compensation policy, and supporting the of variable pay plans such as annual bonus and sales incentive schemes.

 

Padmashree-Santosh-270×260

Padmashree Santosh

Associate Director Talent & Development- South APAC

Merck

Padmashree Santosh (Paddy), PCC is an Experienced Talent Development Director, with over 14 years’ experience in Asia with broad range of experience in diverse industries. Enjoys partnering with business to build strategically-aligned leadership capability through deep people engagement. She has profound knowledge and experiences in cross culture environment and cross cultural teams and rich experiences in design and delivery of team interventions and change management globally. She is a professional Coach with International Coaching Federation and has various accreditations like BlenChart (Situational Team Leadership), Leadership Grid facilitator by Grid USA, Accredited on Myers-Briggs Type Indicator.